<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072485</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-37203</org_study_id>
    <nct_id>NCT03072485</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers</brief_title>
  <official_title>Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study in healthy adult volunteers to examine the effects of 3 FDA approved&#xD;
      medications on skin aging when applied in topical form. This is an open label, placebo&#xD;
      controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of the study is the profile of differences in transcript levels of&#xD;
      age-associated genes such as those in the lamin-A, insulin like growth factor (IGF) and NFKB&#xD;
      pathways as well as noncoding RNAs in topical agent-exposed arm skin versus placebo exposed&#xD;
      arm skin in healthy volunteers. The secondary endpoints include (1) differences in skin&#xD;
      wrinkling using a 4 point Likert scale for wrinkle severity between placebo and topical agent&#xD;
      exposed arm skin after 4 weeks of usage; (2) the type and severity of adverse events, both&#xD;
      systemic and skin localized after exposure to both topical agent and placebo vehicle cream.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">February 22, 2019</completion_date>
  <primary_completion_date type="Actual">February 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of gene transcript changes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Profile of gene transcript changes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wrinkle score</measure>
    <time_frame>4 weeks</time_frame>
    <description>on Likert scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First five enrolled participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin, diclofenac</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sixth to tenth enrolled participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Topical sirolimus applied to the skin</description>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Topical metformin applied to the skin</description>
    <arm_group_label>Metformin, diclofenac</arm_group_label>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Topical diclofenac applied to the skin</description>
    <arm_group_label>Metformin, diclofenac</arm_group_label>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age greater than or equal to 55 years&#xD;
&#xD;
          2. Female&#xD;
&#xD;
          3. All 4 grandparents of European descent&#xD;
&#xD;
          4. Fitzpatrick Skin type 1-3 (fair skin type)&#xD;
&#xD;
          5. Presence of moderate to severe fine wrinkling on arm skin&#xD;
&#xD;
          6. Presence of moderate to severe dyspigmentation on arm skin&#xD;
&#xD;
          7. Normal or overweight body mass index&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of laser treatment or chemical peels to to arm&#xD;
&#xD;
          2. History of topical anti-aging products (includes retinol, tretinoin, tazarotene,&#xD;
             azelaic acid, hydroquinone) to skin within 6 weeks of starting study&#xD;
&#xD;
          3. History of surgical procedures to arm skin area including removal of benign or&#xD;
             malignant skin cancers in the area of topical study agent application&#xD;
&#xD;
          4. Current skin conditions in the area of arms including seborrheic keratosis, rosacea,&#xD;
             eczema that may obscure study assessment&#xD;
&#xD;
          5. History of abnormal scarring&#xD;
&#xD;
          6. Uncontrolled medical problems including concurrent infection or malignancy at time of&#xD;
             enrollment&#xD;
&#xD;
          7. Unable to provide and sign written informed consent&#xD;
&#xD;
          8. Unable to comply with study-related procedures including keeping study diary,&#xD;
             application of topical study agents, avoidance of direct sun exposure &gt;5 minutes per&#xD;
             day or ultraviolet tanning bed usage&#xD;
&#xD;
          9. Not willing to provide two small skin biopsies at end of study&#xD;
&#xD;
         10. Known allergy to sirolimus, diclofenac or metformin.&#xD;
&#xD;
         11. Known immunosuppression including organ transplant, HIV, autoimmune disease, and&#xD;
             chronic leukemia or lymphoma&#xD;
&#xD;
         12. Fasting blood sugar above the upper limit of normal for Stanford laboratory&#xD;
&#xD;
         13. Diarrhea&#xD;
&#xD;
         14. Use of greater than one alcoholic beverage per day&#xD;
&#xD;
         15. Stress such as surgery or trauma within 2 weeks of enrollment&#xD;
&#xD;
         16. Liver disease such as hepatitis B or C&#xD;
&#xD;
         17. Planning to embark on dieting, caloric restriction or new exercise regimen during the&#xD;
             study to lose weight.&#xD;
&#xD;
         18. Unable to refrain from using any topical agent on arms besides the study agents&#xD;
             provided for duration of study.&#xD;
&#xD;
         19. Hematocrit, hemoglobin, platelets, white blood cell count, serum Na, K, Cr, aspartate&#xD;
             aminotransferase (AST), alanine aminotransferase (ALT) greater or lesser than 1.5&#xD;
             times limits of normal.&#xD;
&#xD;
         20. History of heart failure, coronary artery disease, including angina, coronary artery&#xD;
             bypass graft, pacemaker or stent placement&#xD;
&#xD;
         21. History of bleeding or ulcers of the gastrointestinal tract&#xD;
&#xD;
         22. History of diabetes mellitus&#xD;
&#xD;
         23. Current use of blood thinners (includes heparin, warfarin and aspirin)&#xD;
&#xD;
         24. Current use of strong cytochrome P 450 (CYP) 3A4 inhibitor and/or P-gp (examples&#xD;
             include ketoconazole, voriconazole, itraconazole, erythromycin, clarithromycin) or&#xD;
             strong inducers of CYP3A4 and/or P-gp (examples include rifampin or rifabutin)&#xD;
&#xD;
         25. Abnormal lipid panel as defined by upper limit of normal at Stanford laboratory&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Dermatology</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>March 28, 2019</last_update_submitted>
  <last_update_submitted_qc>March 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anne Chang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>aging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

